Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation

Zhi-min Zeng1,2 | Peng Xu1,2 | Shan Zhou1 | Hai-yang Du1 | Xiao-liu Jiang1 | Jing Cai1 | Long Huang1,2 | An-wen Liu1,2

1Department of Oncology, The second affiliated hospital of Nanchang University, Nanchang, China
2Jiangxi key laboratory of clinical translational cancer research, The second affiliated hospital of Nanchang University, Nanchang, China

Correspondence
Long Huang and An-wen Liu, Department of Oncology, The Second Affiliated Hospital of Nanchang University, 330006, Nanchang, Jiangxi, China; Jiangxi key laboratory of clinical translational cancer research, The second affiliated hospital of Nanchang University Nanchang, 330006, Nanchang, Jiangxi, China.

Emails: huangleoldoctor@163.com (HL); awliu666@163.com (LA-w)

Funding information
This work was supported by the National Natural Science Foundation of China [grant number 81560509 81760566 and 81960571], Key Research and Development Project of Jiangxi province [grant number 20192ABK700013, 20181ACG70051], Science and Technology Innovation Outstanding Young talents training Program of Jiangxi Province[grant number20192BCBL30023].

Abstract
Background: Early screening and diagnosis of radiation-induced heart disease (RIHD) is difficult in patients with chest radiation exposure. sST-2 is involved in myocardial stress or injury. We evaluated the relationship between heart dose parameters and sST-2 changes in chest malignant tumor patients who received chest radiation.

Methods: We prospectively collected thoracic malignancy cancer patients who had received chest radiotherapy. Heart dosimetry parameters were extracted from the treatment planning system. sST-2 was measured at baseline, the middle stage, and after radiotherapy (recorded as pre-ST-2, mid-ST-2, and post-ST-2). sST-2 change rate was calculated. Scatter plots showed the relationship between cardiac dose parameters and ST-2 change rate. Multiple regression was used to analyze the relationship between cardiac dose parameters and ST-2 change rate.

Results: Totally, 60 patients were enrolled. The mean V5, V10, V20, V30, V40, and MHD was 60.93 ± 27.79%, 51.43 ± 25.44%, 39.17 ± 21.75%, 28.07 ± 17.15%, 18.66 ± 12.18%, and 18.60 ± 8.63 Gy, respectively. The median M-LAD was 11.31 (IQR 3.33-18.76) Gy. The mean pre-ST-2, mid-ST-2, and post-ST-2 was 5.1 ± 3.8, 6.4 ± 3.9, and 7.6 ± 4.4, respectively. sST-2 was elevated with thoracic irradiation (P < .001). Multivariate linear regression analyses showed that V5, V10, V20, and MHD were independently positively associated with ST-2 change rate (β = .04, .04, .04, and .10, respectively, all P < .05).

Conclusion: Serum sST-2 levels were elevated over time during radiotherapy. V5, V10, V20 and MHD were independently and positively associated with the elevated ST-2 change rate.

KEYWORDS
cardiac biomarker, heart dosimetry parameters, radiation-induced heart disease, radiotherapy, sST-2

Abbreviations: BNP, B-type natriuretic peptide; DVH, dose-volume histogram; IMRT, intensity-modulated radiotherapy; IQR, interquartile range; LVEF, the left ventricle ejection fraction; MHD, mean heart dose; M-LAD, mean dose of left anterior descending artery; RIHD, radiation-induced heart disease; RT, radiotherapy; sST-2, solubleST-2; VMRT, volumetric-modulated radiotherapy.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2019 The Authors. Journal of Clinical Laboratory Analysis Published by Wiley Periodicals, Inc.
1 | INTRODUCTION

Thoracic radiotherapy (RT) is one of the main treatments for lung cancer, esophageal cancer, and thymoma. Cardiotoxicity is a serious problem threatening the survival and quality of life of patients undergoing thoracic radiotherapy. A large number of studies have shown that RIHD can occur in patients with breast cancer, childhood lymphoma, and other cancers decades after radiotherapy. Until now, there was no standard diagnostic method for RIHD. Myocardial markers (including brain natriuretic peptide (BNP), pro-BNP, and cTnI), echocardiography, and cardiac magnetic resonance are common methods for diagnosing RIHD. Early screening and diagnosis of RIHD are difficult in patients with radiation exposure.

ST-2 is a member of the interleukin-1 receptor family and includes transmembrane (ST-2L) and soluble ST-2 isoforms (sST-2). IL-33 is a specific ligand of ST-2L, forming the IL-33/ST-2 signaling pathway, which is involved in myocardial stress or injury. Multiple studies revealed that elevated sST-2 concentration is involved in various heart diseases, such as heart failure, atrial fibrillation, heart transplant recipients, chronic kidney disease-induced cardiac remodeling, and myocardial infarction. The guidelines for heart failure management issued by ACCA/AHA in 2013 recommend soluble ST-2 as an additional indicator of risk stratification in patients with acute and chronic heart failure.

Heart radiation exposure can lead to vascular endothelial cell damage and vascular inflammatory reactions, resulting in interstitial ischemic fibrosis caused by thrombosis or inflammatory reactions. A study demonstrated that sST-2 levels in workers from the nuclear industry were significantly higher (fivefold) than the control group without exposure history. When patients receive chest radiotherapy, the heart is exposed to large doses of X-rays in a short duration, especially in central lung tumors and esophageal cancer. However, the effect of chest radiation on sST-2 and whether changes in sST-2 levels are associated with cardiac doses was unclear.

In this study, we examined sST-2 levels in the serum of patients receiving high-dose radiotherapy for thoracic malignancies. We evaluated early changes in serum sST-2 levels during thoracic radiotherapy and determined associations between heart dosimetry parameters and ST-2 change rate.

2 | METHODS AND MATERIALS

2.1 | Patients and study design

Patients with malignant thoracic tumors who underwent thoracic RT in the Department of Thoracic Oncology, Second Affiliated Hospital of Nanchang University from October 2016 to August 2018 were enrolled in this study. All patients had received thoracic irradiation, including radical radiotherapy, adjuvant radiotherapy, or palliative radiotherapy. Each patient underwent sST-2 and BNP determination before RT (recorded as pre-ST-2 or pre-BNP), in the middle of RT (recorded as mid-ST-2 or mid-BNP), and after the end of RT (recorded as post-ST-2 or post-BNP). Echocardiography was performed before and after RT (recorded as pre-left ventricular ejection fraction (pre-LVEF) or post-LVEF).

Inclusion criteria were as follows: age >18 years, Eastern Cooperative Oncology Group performance status 0-2, and adequate hematologic, hepatic, and renal function. Exclusion criteria were as follows: the presence of another primary cancer (excluding skin cancer beyond 5 years), thoracic radiation historically, malignant pericardial effusion, uncontrolled angina pectoris, myocardial infarction <3 months before enrollment, interstitial pneumonia, active lung fibrosis, or severe cachexia. All enrolled patients provided consent and the study was approved by the Ethics Committee of the Second Affiliated Hospital of Nanchang University.

2.2 | Serum sST-2 and BNP array

Blood samples were collected in tubes with EDTA and serum was separated by centrifugation for 10 min at 600 × g. The serum samples were stored at −80°C for later use. sST-2 was determined using a high-sensitivity enzyme-linked assay (ELISA) kit (Presage ST-2 assay; Critical Diagnostics) according to the manufacturer’s procedures. sST-2 levels were evaluated after determining the optical density of the samples at 450 nm (Thermo Scientific Microplate Reader, Varioskan LUX). BNP was detected in our clinical laboratory collected in medical record system.

2.3 | Cardiac echocardiography

Cardiac echocardiographic examinations were performed using GE Vivid (GE Healthcare, Vivid E9) by experienced physicians who were blinded to all treatment data. LVEF was collected before and after radiotherapy.

2.4 | Irradiation

All patients received intensity-modulated or volumetric-modulated RT (IMRT or VMRT) using an Elekta linear accelerator (Elekta Versa HD) in a supine position fixed with mask or vacuum bag. The targets and organs at risk (OAR), including the heart, were contoured by the same physician, and the treatment plan was designed by a specific physician. The dose of normal tissues was constrained (lung of V<sub>20</sub> <32%, V<sub>30</sub> <20%, heart of V<sub>40</sub> <30%). The dosage of RT was as follows: 5040-6400 cGy/28-32F for thymoma, 4500-6720cGy/28-32F for esophageal cancer, 4500 cGy/15F × BID or 5040-6400 cGy/28-32F for small cell lung cancer, and 5040-6600 cGy/28-32F for non-small cell lung cancer. Heart dosimetry parameters, including V<sub>5</sub>, V<sub>10</sub>, V<sub>20</sub>, V<sub>30</sub>, V<sub>40</sub> the mean dose of the heart (MDH), and the mean dose of the left anterior descending coronary artery (M-LAD), were extracted from the
dose-volume histogram (DVH) curves in the Monaco treatment planning system (Elekta Versa HD).

### 2.5 | Statistical analysis

Data are presented as mean ± SD or median (interquartile range, IQR) for continuous variables and as frequency (%) for categorical variables. We used either two-tailed t test/paired t test or the Wilcoxon rank-sum test for comparison of two groups. ST-2 change rate was calculated by subtracting pre-ST-2 from post-ST-2 and then dividing it by pre-ST-2. Multivariate linear regression analyses were used to assess the β and 95% confidence interval (CI) of cardiac dose parameters associated with ST-2 change rate, with adjustment for major covariates including age, gender, smoking, history of coronary disease, diabetes mellitus, hypertension, chemotherapy, and surgery. The smooth curve fitting (penalized spline method) was used to characterize the shape of the associations between heart dose parameters and ST-2 change rate. All analyses were performed using the statistical package R (http://www.R-project.org, The R Foundation) and Empower (R) (www.empowerstats.com; X&Y Solutions, Inc). A 2-tailed \( P < .05 \) was considered statistically significant.

### 3 | RESULTS

#### 3.1 | Population characteristics

Demographic data in the study are shown in Table 1. A total of 60 patients who received chest RT were enrolled, including patients with lung cancer (61.67%), esophageal cancer (30%), and thymoma (8.33%). The mean age was 61.5 years (range 30-84). Among them, two had a history of coronary heart disease, five had diabetes mellitus, and 10 had hypertension. Of the 60 patients, 42 (70%) had received radical RT, 16 (26.7%) adjuvant RT, and 2 (3.3%) palliative RT.

| Characteristic | Value |
|---------------|-------|
| Age           | 61.8 ± 9.6 |
| Gender        | Male 52 (86.67%), Female 8 (13.33%) |
| Smoking       | No 33 (55.00%), Yes 27 (45.00%) |
| History of coronary disease | No 58 (96.67%), Yes 2 (3.33%) |
| Diabetes mellitus | Without 55 (91.67%), With 5 (8.33%) |
| Hypertension  | Without 50 (83.33%), With 10 (16.67%) |
| Chemotherapy  | No 12 (20.00%), Yes 48 (80.00%) |
| Surgery       | No 34 (56.67%), Yes 26 (43.33%) |
| Type of pathology | Lung cancer 37 (61.67%), Esophagus cancer 18 (30.00%), Thymoma 5 (8.33%) |
| Type of rt    | Radical 42 (70%), Adjuvant 16 (26.7%), Palliative 2 (3.3%) |

Abbreviations: RT, radiotherapy.

*Data are presented as number (%) or mean ± standard deviation.

**TABLE 1** Characteristics of patients

![FIGURE 1](image)  
**FIGURE 1** Serum ST-2 level changes in different periods of RT. A, Distribution of sST-2 levels between pre-ST-2 and mid-ST-2; B, Distribution of sST-2 levels between mid-ST-2 and post-ST-2; C, Distribution of sST-2 levels between pre-ST-2 and post-ST-2
3.2 | sST-2 levels were elevated with the time of thoracic irradiation, while LVEF and BNP levels were not changed

We evaluated cardiac function changes using cardiac ultrasonography and serum cardiac biomarkers. Among the patients, the mean pre-sST-2, mid-sST-2, and post-sST-2 levels were 5.1 ± 3.8, 6.4 ± 3.9, and 7.6 ± 4.4, respectively. mid-sST-2 and post-sST-2 levels were significantly higher than pre-sST-2 levels (Figure 1 A). As shown in Figure 1, after RT and in comparison with pre-sST-2, mid-sST-2 level increased in 65.4% of patients; post-sST-2 levels were increased in 71.2% patients. ST-2 levels (75%) were elevated from mid-sST-2 to post-sST-2.

The median pre-BNP, mid-BNP, and post-BNP levels were 22.56 (IQR 7.25-63.5), 32.25(IQR 18.85-52.97), and 32.41 (IQR 17.23-55.97), respectively. However, there was no significant difference in BNP levels with the course of RT (Figure S1A). The mean pre-LVEF and post-LVEF were 64.36 and 62.76, respectively (Figure S1B), with no significant difference (P > .05).

3.3 | Association between heart dose parameters and levels of ST-2

The mean $V_5$, $V_{10}$, $V_{30}$, $V_{40}$, and MHD was 60.93 ± 27.79%, 51.43 ± 25.44%, 39.17 ± 21.75%, 28.07 ± 17.15%,18.66 ± 12.18%, and 18.60 ± 8.63 Gy, respectively. The median M-LAD was 11.31 (IQR 3.33-18.76) Gy. The association of cardiac dose parameters with ST-2 change rate, as assessed by multivariate linear regression analysis, is listed in Table 2. In the non-adjusted model, $V_5$, $V_{10}$, $V_{30}$, and MHD were significantly and positively associated with ST-2 change rate ($\beta = .03, .04, .04, and .09$, respectively, all P < .05). After adjustment for age and gender, $V_5$, $V_{10}$, $V_{30}$, and MHD were independently and positively associated with ST-2 change rate ($\beta = .03, .03, .04, .04, and .09$, respectively, all P < .05). In addition, after adjustment for all confounding factors including age, gender, smoking, history of coronary disease, diabetes mellitus, hypertension, chemotherapy, and surgery, $V_5$, $V_{10}$, $V_{30}$, and MHD were still independently and positively associated with ST-2 change rate ($\beta = .04, .04, .04, and .1$, respectively, all P < .05).

Further analysis using smooth curve fitting (penalized spline method) confirmed that the association between heart dose parameters and ST-2 change rate was linear (Figure 2).

4 | DISCUSSION

We found that heart dose parameters in thoracic malignant tumor patients are associated with a change in ST-2 change rate, when they received chest RT. Our results showed that compared with baseline, ST-2 levels increased over time. However, compared with pre-LVEF levels, post-LVEF levels were not different, and the traditional cardiac biomarker BNP levels were also not changed. A positive association between heart dose parameters and ST-2 change rate was found.

Despite the rapid progress in cancer screening, diagnosis, and treatment, treatment-related cardiovascular events such as radiation-induced cardiac injury remain unavoidable. LVEF and blood markers (NT-pro-BNP/BNP and cTnI) are still classical methods in clinical practice for the risk assessment, diagnosis, and management of RIHD. In the small sample longitudinal study of cardiac biomarkers in patients receiving thoracic radiotherapy, Gomez et al. showed that BNP increases during high-dose irradiation of the heart in some patients. Recently, a long-term retrospective study reported that median plasma BNP levels in 5-year breast cancer survivors after radiation therapy remain within the normal range, but the delta-BNP levels are positively related to the mean heart dose and mean left ventricular dose received. However, the significance of BNP in the diagnosis and evaluation of radiation-induced cardiac disease is not fully understood. Our results showed that BNP had not changed after RT, compared with BNP at the baseline, indicating BNP would not increase in short-term post-radiation therapy.

### Table 2: Relationship between heart dose parameters and ST change rate in different models

| Variables | Non-adjusted model | Adjusted model I | Adjusted model II |
|-----------|---------------------|-----------------|------------------|
|           | $\beta$ (95%CI) | P-value | $\beta$ (95%CI) | P-value | $\beta$ (95%CI) | P-value |
| $V_5$     | .03 (0.01, 0.06) | .0084   | .03 (0.01, 0.05) | .0127   | .04 (0.01, 0.06) | .0047   |
| $V_{10}$  | .04 (0.01, 0.06) | .0081   | .03 (0.01, 0.06) | .0106   | .04 (0.01, 0.07) | .0055   |
| $V_{20}$  | .04 (0.01, 0.07) | .0122   | .04 (0.01, 0.07) | .0181   | .04 (0.01, 0.07) | .0146   |
| $V_{30}$  | .04 (0.00, 0.08) | .0441   | .04 (−0.00, 0.08) | .0647   | .04 (−0.00, 0.08) | .0572   |
| $V_{40}$  | .03 (−0.02, 0.09) | .2285  | .03 (−0.03, 0.09) | .2738   | .04 (−0.02, 0.10) | .1893   |
| MHD       | .09 (0.01, 0.17) | .0257   | .09 (0.01, 0.16) | .0341   | .10 (0.02, 0.18) | .0187   |
| M-LAD     | .05 (−0.02, 0.13) | .1913  | .04 (−0.03, 0.12) | .2526   | .05 (−0.03, 0.13) | .2419   |

Note: Non-adjusted model adjusted for: None.

Adjusted model I adjusted for: age and gender.

Adjusted model II adjusted for: age, gender, smoking, history of coronary disease, diabetes mellitus, hypertension, chemotherapy, and surgery.

Abbreviations: CI, confidence interval; MHD, mean heart dose; M-LAD, mean dose of left anterior descending artery; $V_5$, volume of heart receiving ≥5 Gy, $V_{10}$, $V_{20}$ and so on.

The left ventricle ejection fraction plays an important role in detecting cardiac function changes. Nousiainen et al.\(^{25}\) demonstrated that early LVEF decline during doxorubicin therapy is associated with doxorubicin cardiotoxicity in lymphoma patients. However, Bianet al.\(^{26}\) found no acute changes in LVEF in breast cancer patients with concurrent trastuzumab and breast radiation. In this study, although the heart dose was higher than in the Bian et al study, the post-LVEF levels were also not changed compared with baseline LVEF (pre-LVEF) levels. Interestingly, we found that sST-2 was increased during RT. Thus, sST-2 might be useful in detecting acute or subclinical cardiotoxicity.

Accumulated results from clinical studies have shown that high cardiac radiation dose is directly associated with RIHDs.\(^{24,27-29}\) Oncologists must also consider the rate of cancer control and the dose of cardiac radiation when formulating a RT regimen. In childhood cancer survivors, a large sample case control study revealed that heart failure often occurred in patients that received \(\geq 30\) Gy to the median volume of the heart.\(^{30}\) In stage III non-small-cell lung cancer, different cardiac events were associated with distinct heart volume doses; for example, ischemic events were correlated with left ventricle and whole heart dose.\(^{27}\) The mean \(V_5, V_{10}, V_{20}, V_{30}, V_{40}\) and MHD in our study was 60.93%, 51.43%, 39.17%, 28.07%, 18.66%, and 18.60 Gy. Our study demonstrated that \(V_5, V_{10}, V_{20}\) and MHD were independently and positively associated with ST change rate (\(\beta = .04,.04,.04, \text{and } .10\), respectively, all \(P < .05\)).

We recognize that the study presents several limitations. First, this is a longitudinal study with a small sample size. Moreover, we collected serum samples only during and after radiotherapy, which mainly reflects acute radiation-induced cardiac injury. Therefore, a long-term follow-up study with a large sample size is warranted.

Fortunately, a registered clinical study\(^ {31}\) on early detection of RIHD is under way. Despite these limitations, this study analyzed the relationship between cardiac dose parameters and ST change rate for the first time in patients with chest radiation exposure and confirmed a linear relationship between them.

5 | CONCLUSION

In conclusion, we showed that sST-2 levels were elevated during radiotherapy over time in patients with thoracic malignant tumors when they received chest RT, and \(V_5, V_{10}, V_{20}\), and MHD were independently and positively associated with ST-2 change rate.

ACKNOWLEDGEMENTS

The authors would like to thank Zou Bing of the Radiotherapy Center for his help in collecting radiation heart dose parameters and Hu Lihua, Department of Cardiovascular Medicine, for his help in part of data processing.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

AUTHORS’ CONTRIBUTIONS

Z-M Z, in charge of design of the work, analysis, and wrote the article. P X, S Z, helped with acquisition and analysis of the data. X-L J and J C helped to collect the serum samples. L H and A-W L, the Corresponding author, was in charge of guidance of the design and analysis the whole research. All authors read and approved the final manuscript.
ETHICS COMMITTEE
The study was consented by all the enrolled patients and the Ethics Committee of the second affiliated hospital of Nanchang University.

DATA AVAILABILITY STATEMENT
The datasets used and analyzed during the study are available from the corresponding author on reasonable request, except private information of participants.

ORCID
Zhi-min Zeng https://orcid.org/0000-0003-0959-3044
An-wen Liu https://orcid.org/0000-0003-4012-9717

REFERENCES
1. Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC) - ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl 4):iv1-iv21.
2. Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16-23.
3. Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v50-v57.
4. Scorsetti M, Leo F, Trama A, et al. Thymoma and thymic carcinomas. Critical Rev Oncol Hematol. 2016;99:332-350.
5. Shellburne N, Adhikari B, Breil J, et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst. 2014;106(9).
6. Guberina M, Eberhardt W, Stuschke M, et al. Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial. Ann Oncol. 2017;28(5):1084-1089.
7. van Nimwegen FA, Ntentes G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017;129(16):2257-2265.
8. Zhu Q, Kirova YM, Cao L, Arsen-Henry A, Chen J. Cardiotoxicity associated with radiotherapy in breast cancer: a question-based review with current literatures. Cancer Treat Rev. 2018;68:9-15.
9. Villarraga HR, Hermann J, Nkomo VT. Cardio-oncology: role of echocardiography. Prog Cardiovasc Dis. 2014;57(1):10-18.
10. Dattagupta A, Immaneni S. ST2: current status. Indian Heart J. 2018;70(Suppl 1):S96-s101.
11. Seki K, Sanada S, Kudinova AY, et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail. 2009;2(6):684-691.
12. deFilippis C, Daniels LB, Bayes-Genis A. Structural heart disease and ST2: cross-sectional and longitudinal associations with echocardiography. Am J Cardiol. 2015;115(7 Suppl):S96-63b.
13. Yaney CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. Circulation. 2013;128(16):e240-e327.
14. Pascual-Figal DA, Perez-Martinez MT, Asensio-Lopez MC, et al. Pulmonary production of soluble ST2 in heart failure. Circ Heart Fail. 2018;11(12):e005488.
15. Boman K, Thormark Fröst F, Bergman AR, Olofsson M. NTPRBNP and ST2 as predictors for all-cause and cardiovascular mortality in elderly patients with symptoms suggestive for heart failure. Biomarkers. 2018;23(4):373-379.
16. Ma X, Yuan H, Luan HX, Shi YL, Zeng XL, Wang Y. Elevated soluble ST2 concentration may involve in the progression of atrial fibrillation. Clinica Chimica Acta. 2018;480:138-142.
17. Mathews LR, Lott JM, Isse K, et al. Elevated ST2 distinguishes incidences of pediatric heart and small bowel transplant rejection. American J Transplant. 2016;16(3):938-950.
18. Grupper A, AbouEzzeddine OF, Maleszewski JJ, et al. Elevated ST2 levels are associated with antibody-mediated rejection in heart transplant recipients. Clin Transplant. 2018;32(9):e13349.
19. Plawecki M, Morena M, Kuster N, et al. sST2 as a new biomarker of chronic kidney disease-induced cardiac remodeling: impact on risk prediction. Mediators Inflamm. 2018;2018:1-9.
20. Bière L, Garcia G, Guillou S, et al. ST2 as a predictor of late ventricular remodeling after myocardial infarction. Int J Cardiol. 2018;259:40-42.
21. Katsarska O, Zaharieva E, Aneva N, Savova G, Stankova K, Boteva R. The soluble receptor ST2 is positively associated with occupational exposure to radiation. J Radiat Biol. 2016;92(2):87-93.
22. Yu AF, Ky B. Roadmap for biomarkers of cancer therapy cardiotoxicity. Heart. 2016;102(6):425-430.
23. Gomez DR, Yusuf SW, Munsell MF, et al. Prospective exploratory analysis of cardiac biomarkers and electrocardiogram abnormalities in patients receiving thoracic radiation therapy with high-dose heart exposure. J Thorac Oncol. 2014;9(10):1554-1560.
24. Portaliur M, Petruzelli MF, Tramacere F, Andreassi MG. B-type natriuretic peptide plasma level in 5-year breast cancer survivors after radiotherapy. Int J Radiat Biol. 2019;95(2):201-206.
25. Nousiainen T, Jantunen E, Vanninen E, Hartikainen J. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients. Br J Cancer. 2002;86(11):1697-1700.
26. Bian SX, Korah MP, Whitaker TR, Ji L, Groschen S, Chung E. No acute changes in LVEF observed with concurrent trastuzumab and breast radiation with low heart doses. Clin Breast Cancer. 2017;17(7):510-515.
27. Wang K, Pearlstein KA, Patchett ND, et al. Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. Radiother Oncol. 2017;125(2):293-300.
28. Wollschläger D, Karle H, Stockinger M, et al. Predicting heart dose in breast cancer patients who received 3D Conformal radiation therapy. Health Phys. 2017;112(1):1-10.
29. Gagliardi G, Constine LS, Moiseenko V, et al. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S77-85.
30. Mansouri I, Allodji RS, Hill C, et al. The role of irradiated heart and left ventricular volumes in heart failure occurrence after childhood cancer. Eur J Heart Fail. 2019;21(4):509-518.
31. Walker V, Crijns A, Langendijk J, et al. Early detection of cardiovascular changes after radiotherapy for breast cancer: protocol for a European multicenter prospective cohort study (MEDIRAD EARLY HEART Study). JMIR research protocols. 2018;7(10):e178.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Zeng Z-M, Xu P, Zhou S, et al. Positive association between heart dosimetry parameters and a novel cardiac biomarker, solubleST-2, in thoracic cancer chest radiation. J Clin Lab Anal. 2020;34:e23150. https://doi.org/10.1002/jcla.23150